Ideaya Biosciences Inc is a biotechnology company focused on the discovery and development of targeted therapeutics for the treatment of cancer
The company employs a precision medicine approach, leveraging its proprietary platform to identify and validate novel drug targets within various cancer types. By integrating advanced techniques in genomics and bioinformatics, Ideaya aims to create innovative therapies that specifically address the underlying genetic and molecular drivers of cancer, ultimately improving patient outcomes and extending survival. Its research pipeline includes a range of drug candidates currently in various stages of clinical development, demonstrating the company's commitment to advancing science and addressing unmet medical needs in oncology.
Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas. ImmuneOnco will receive an upfront and near-term payments of $50 million, and up to more than $2 billion in milestones.
IDEAYA Biosciences reports promising Phase 2 clinical data for IDE397 in MTAP-deletion urothelial and NSCLC patients. The study shows a 39% overall response rate, 94% disease control rate, and a favorable adverse event profile, highlighting IDE397's potential as a monotherapy.
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.
